TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US)
Phase 2CompletedDevelopment Stage
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Mar 22, 2019 → Oct 2, 2021
About TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US)
TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US) is a phase 2 stage product being developed by Sagimet Biosciences for MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis). The current trial status is completed. This product is registered under clinical trial identifier NCT03938246. Target conditions include MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis).
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03938246 | Phase 2 | Completed |